CTMX

CytomX Therapeutics Stock Price

6.72
0.12 (1.82%)
Upgrade to Real-Time
Afterhours (Closed)
6.72
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
CytomX Therapeutics Inc CTMX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.12 1.82% 6.72 19:58:06
Open Price Low Price High Price Close Price Prev Close
6.84 6.53 6.88 6.65 6.60
Bid Price Ask Price Spread News
6.71 6.72 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
15,762 2,320,579 $ 6.68 $ 15,509,382 820,177 3.60 - 15.44
Last Trade Time Type Quantity Stock Price Currency
19:58:06 formt 465 $ 6.72 USD

CytomX Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 310.63M 46.22M 45.02M $ 57.49M $ -12.45M -2.26 -7.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

CytomX Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CTMX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.838.556.537.042,327,394-1.11-14.18%
1 Month7.458.556.437.09826,885-0.73-9.8%
3 Months6.768.556.407.29597,167-0.04-0.59%
6 Months8.268.556.257.17498,437-1.54-18.64%
1 Year7.6315.443.607.84525,478-0.91-11.93%
3 Years25.7035.003.6012.57450,964-18.98-73.85%
5 Years14.9735.003.6013.45346,520-8.25-55.11%

CytomX Therapeutics Description

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.


Your Recent History
NASDAQ
CTMX
CytomX The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.